Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Current Assets: 2015-2025

Historic Current Assets for Syndax Pharmaceuticals (SNDX) over the last 10 years, with Sep 2025 value amounting to $529.8 million.

  • Syndax Pharmaceuticals' Current Assets rose 27.73% to $529.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $529.8 million, marking a year-over-year increase of 27.73%. This contributed to the annual value of $603.1 million for FY2024, which is 3.82% up from last year.
  • Latest data reveals that Syndax Pharmaceuticals reported Current Assets of $529.8 million as of Q3 2025, which was down 0.35% from $531.7 million recorded in Q2 2025.
  • Syndax Pharmaceuticals' 5-year Current Assets high stood at $603.1 million for Q4 2024, and its period low was $238.3 million during Q3 2021.
  • Its 3-year average for Current Assets is $485.5 million, with a median of $453.9 million in 2024.
  • Data for Syndax Pharmaceuticals' Current Assets shows a peak YoY skyrocketed of 167.69% (in 2021) over the last 5 years.
  • Syndax Pharmaceuticals' Current Assets (Quarterly) stood at $448.4 million in 2021, then climbed by 9.23% to $489.8 million in 2022, then grew by 18.60% to $580.9 million in 2023, then rose by 3.82% to $603.1 million in 2024, then rose by 27.73% to $529.8 million in 2025.
  • Its Current Assets stands at $529.8 million for Q3 2025, versus $531.7 million for Q2 2025 and $548.8 million for Q1 2025.